Company news
Ligand Pharmaceuticals Incorporated (NASDAQ:LGND) news
Every Ligand Pharmaceuticals Incorporated press release and news update in one place — announcements, filings coverage, and company updates for investors.
Press releases & updates
Ligand to Report Second Quarter 2026 Financial Results on August 6, 2026
July 23, 2026
Ligand Completes Acquisition of XOMA Royalty, Creating a Portfolio of More than 200 Biopharmaceutical Royalty Assets
July 14, 2026
XOMA Royalty Announces Closing of Its Acquisition by Ligand
July 14, 2026
Ligand Announces Pricing of Upsized $625 Million Convertible Senior Notes Offering
June 23, 2026
Ligand Announces Proposed Offering of $550 Million of Convertible Senior Notes Due 2031
June 22, 2026
XOMA Royalty : Ligand to Acquire XOMA Royalty, Further Accelerating Profit Growth and Strengthening Ligand’s Position as a Leading Biopha...
June 12, 2026
Ligand Announces 2026 Investor Day in New York City
June 10, 2026
Ligand to Participate in June Investor Conferences
May 27, 2026
Ligand Reports First Quarter 2026 Financial Results
May 7, 2026
Orchestra BioMed Receives $15 Million Investment from Ligand Under Previously Announced Strategic Financing Agreement
May 6, 2026
Ligand to Acquire XOMA Royalty, Further Accelerating Profit Growth and Strengthening Ligand’s Position as a Leading Biopharma Royalty Agg...
April 27, 2026
Ligand to Report First Quarter 2026 Financial Results on May 7, 2026
April 22, 2026
Ligand Partner Travere Therapeutics Receives Full FDA Approval for FILSPARI® (sparsentan) in FSGS
April 14, 2026
Ligand Advances Strategic Growth with Expanded and Strengthened Business Development Team
March 26, 2026
Ligand Reports Fourth Quarter and Full Year 2025 Financial Results
February 26, 2026
Ligand to Report Fourth Quarter and Full Year 2025 Financial Results on February 26, 2026
February 12, 2026
Ligand to Present at the Oppenheimer 36th Annual Healthcare Life Sciences Conference
February 4, 2026
Ligand Hosts 2025 Investor Day and Introduces 2026 Guidance
December 9, 2025
Ligand Reports Third Quarter 2025 Financial Results and Raises Guidance
November 6, 2025
Ligand to Participate in November Investor Conferences
October 30, 2025
Ligand to Report Third Quarter 2025 Financial Results on November 6, 2025
October 23, 2025
Ligand to Host Investor Day on December 9, 2025
October 16, 2025
Ligand Partner SQ Innovation Receives FDA Approval for Lasix® ONYU, an At-Home Treatment for Edema in Heart Failure Patients
October 9, 2025
Ligand to Participate in September Investor Conferences
August 19, 2025
Ligand Announces Closing of Convertible Senior Notes Offering
August 14, 2025
Ligand Announces Proposed Offering of $400 Million of Convertible Senior Notes Due 2030
August 11, 2025
Ligand Announces Pricing of $400 Million Convertible Senior Notes Offering
August 11, 2025
Ligand Reports Second Quarter 2025 Financial Results and Raises Guidance
August 7, 2025
Orchestra BioMed Secures Over $111 Million in Proceeds and Committed Capital Following Completion of Strategic Transactions and Concurren...
August 5, 2025
Ligand and Medtronic Commit $70 Million in Strategic Capital to Orchestra BioMed
July 31, 2025
Ligand to Report Second Quarter 2025 Financial Results on August 7, 2025
July 24, 2025
LGND Raises $9M to Make Earth Data Intuitive and Actionable
July 10, 2025
Ligand Partner Pelthos Therapeutics Launches ZELSUVMI™
July 10, 2025
Ligand Announces Completion of Pelthos Therapeutics Merger with Channel Therapeutics
July 2, 2025
Ligand Announces 2025 Investor Day in New York City
June 11, 2025
Ligand to Ring the Nasdaq Opening Bell on May 19, 2025
May 14, 2025
Ligand Reports First Quarter 2025 Financial Results
May 8, 2025
Ligand to Participate in May Investor Conferences
May 1, 2025
Ligand to Report First Quarter 2025 Financial Results on May 8, 2025
April 24, 2025
Ligand Subsidiary Pelthos Therapeutics to Combine with Channel Therapeutics
April 17, 2025
Ligand to Participate in March Investor Conferences
March 3, 2025
Ligand Reports Fourth Quarter and Full Year 2024 Financial Results
February 27, 2025
Ligand Leads $75 Million Royalty Financing in Castle Creek Biosciences
February 25, 2025
Ligand to Report Fourth Quarter and Full Year 2024 Financial Results on February 27, 2025
February 13, 2025
Ligand to Present at the Oppenheimer 35th Annual Healthcare Life Sciences Conference
February 6, 2025
Ligand Hosts 2024 Investor and Analyst Day and Introduces 2025 Guidance
December 10, 2024
Ligand to Present at Stifel 2024 Healthcare Conference
November 14, 2024
Ligand Reports Third Quarter 2024 Financial Results and Raises 2024 Guidance
November 7, 2024
Ligand to Host Investor and Analyst Day on December 10, 2024 in Boston
November 1, 2024
Ligand to Report Third Quarter 2024 Financial Results on November 7, 2024
October 23, 2024